Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106492 | 0.81 | BMPR1B (0.40) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL1106489 | 0.80 | TAAR1 (0.34) | BRD4 | |
| SCHEMBL22246178 | 0.76 | BMPR1B (0.37) | BRD4BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL22252035 | 0.75 | BMPR1B (0.36) | BRD4BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL22600101 | 0.75 | BRD4 (0.47) | BRD4CYP19A1NQO2THRB | |
| SCHEMBL1106462 | 0.73 | BRD4 (0.41) | BRD4BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL16650238 | 0.73 | BMPR1B (0.36) | BRD4BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL22246174 | 0.70 | BMPR1B (0.40) | CRHR1BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL1106438 | 0.69 | CA12 (0.39) | BRD4PKMSMN1; SMN2 | |
| SCHEMBL22252037 | 0.67 | HDAC4 (0.43) | BRD4BMPR1BBMPR1ATGFBR1ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CRHR1 3464/4885BRD4 4489/4885BMPR1B 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.